Klinika Okulistyki   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Białystok Poland

Organization Overview

First Clinical Trial
2004
NCT00565123
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Katdra Klinika Okulityki Akademii Medycznej w Warszawie | Katedra i Klinika Hematologii Collegium Medicum | Katedra i klinika Hematologii, Warszawa, Poland | Katedra I Klinika Okulistyki II Wydz. Lek. AM w Warszawie,

Active Ingredients

Drugs in Phase 4 Trials (3)

latanoprost (xalatan) (1 trial)

pilocarpine (ocusert) (1 trial)

timolol (blocadren) (1 trial)

Drugs in Phase 3 Trials (1)

levofloxacin (levaquin) (1 trial)

Drugs in Phase 2 Trials (2)

forodesine (1 trial)

symphoglobulin-d (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Bacterial (Phase 3)

Glaucoma, Open-Angle (Phase 4)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Ocular Hypertension (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6